Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial-Reference-Cited by-同舟云学术

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

Published:2020-07 Issue:7 Volume:21 Page:935-946
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Heinrich Michael C,Jones Robin L,von Mehren Margaret,Schöffski Patrick,Serrano César,Kang Yoon-Koo,Cassier Philippe A,Mir Olivier,Eskens Ferry,Tap William D,Rutkowski Piotr,Chawla Sant P,Trent Jonathan,Tugnait Meera,Evans Erica K,Lauz Tamieka,Zhou Teresa,Roche Maria,Wolf Beni B,Bauer Sebastian,George Suzanne

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden;Nilsson;Cancer,2005

2. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing;Ducimetière;PLoS One,2011

3. Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels

4. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib;Corless;J Clin Oncol,2005

5. Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series;Roubaud;Ann Oncol,2012

Cited by 215 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) Resistance;Cancers;2024-09-07

2. Surgical Management of Gastric Gastrointestinal Stromal Tumors;Surgical Clinics of North America;2024-09

3. Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism Research;Global Medical Genetics;2024-08-22

4. Molecular Profiling of KIT/PDGFRA-Mutant and Wild-Type Gastrointestinal Stromal Tumors (GISTs) with Clinicopathological Correlation: An 18-Year Experience at a Tertiary Center in Kuwait;Cancers;2024-08-21

5. Management of subepithelial esophageal tumors;Innovative Surgical Sciences;2024-08-20